Supplementary Table S3 from SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor–induced growth suppression
Year: 2024
Type: supplementary-materials
Abstract: Supplementary Table S3. Complete listing of antibodies used for immunoblotting (IB) and immunostaining analysis (Fig. 6C, 6D and Extended Data Fig. 5, 6). Vendor and catalog numbers are included in the list.
Authors: Chuandong Geng, Man-Chao Zhang, Ganiraju C. Manyam, Jody V. Vykoukal, Johannes F. Fahrmann, Shan Peng, Cheng Wu, Sanghee Park, Shakuntala Kondraganti, Daoqi Wang, Brian D. Robinson, Massimo Loda, Christopher E. Barbieri, Timothy A. Yap, Paul G. Corn, Samir Hanash, Bradley M. Broom, Patrick G. Pilie, Timothy C. Thompson
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4402789699